Beyond HLA matching: a practical framework for selecting among HLA-identical donors in hematopoietic stem cell transplantation
DOI:
https://doi.org/10.46765/2675-374X.2025v7n1e359Keywords:
Hematopoietic stem cell transplantation , Donor selection, Donor ageAbstract
Background: Donor selection in allogeneic hematopoietic stem cell transplantation (HSCT) has evolved beyond human leukocyte antigen (HLA) compatibility. Advances in transplant platforms and immunogenetics have highlighted the importance of integrating additional donor-related clinical and biological factors. Methods: This Brazilian Society of Bone Marrow Transplantation (SBTMO) consensus was developed through a critical review of the current literatureand expert discussion. It addresses the main variables influencing donor selection beyond HLA matching and provides evidence-based recommendations. Results: Donor age is the most relevant non-HLA factor and should be prioritized whenever possible. Other variables-including cytomegalovirus serostatus, ABO compatibility, donor sex and parity, germline predisposition variants, donor eligibility, and ethical considerations-should be incorporated into an individualized decision-making process. A practical algorithm summarizes the proposed recommendations. Conclusion: Donor selection should integrate HLA compatibility with clinical, biological, and ethical factors to optimize transplant outcomes. This consensus provides a practical framework to support evidence-based donor selection in contemporary allogeneic HSCT.
References
1. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R, Lankester AC, Mohty M, Neven B, Peffault de Latour R, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57(8):1217-39. https://doi.org/10.1038/s41409-022-01691-w DOI: https://doi.org/10.1038/s41409-022-01691-w
2. Sureda A, Corbacioglu S, Greco R, Kröger N, Carreras E, editors. The EBMT Handbook: hematopoietic cell transplantation and cellular therapies. 8th ed. Cham: Springer; 2024. https://doi.org/10.1007/978-3-031-44080-9 DOI: https://doi.org/10.1007/978-3-031-44080-9
3. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaños-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-50. https://doi.org/10.1016/j.bbmt.2008.03.005 DOI: https://doi.org/10.1016/j.bbmt.2008.03.005
4. Spellman SR. Hematology 2022 — what is complete HLA match in 2022? Hematology Am Soc Hematol Educ Program. 2022;2022(1):83-9. https://doi.org/10.1182/hematology.2022000326 DOI: https://doi.org/10.1182/hematology.2022000326
5. Nath K, Zhang MJ, Bye M, Abid MB, Benjamin C, Betts B, Bhatt NS, Arrieta Bolaños E, Bolon YT, Gadalla SM, Grunwald MR, Krem MM, Lee SJ, Marsh SGE, Martino R, Mehta PA, Milano F, Prestidge T, Saultz JN, Shaw BE, Spellman SR, Choe H, Shaffer BC. Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis. Blood Adv. 2025;9(14):3469-78. https://doi.org/10.1182/bloodadvances.2024014858 DOI: https://doi.org/10.1182/bloodadvances.2024014858
6. Piemontese S, Labopin M, Choi G, Broers AEC, Peccatori J, Meijer E, Van Gorkom G, Rovira M, Pascual Cascon MJ, Sica S, Vydra J, Kulagin A, Spyridonidis A, Nagler A, Bazarbachi A, Savani B, Brissot E, Sanz J, Mohty M, Ciceri F. Older MRD vs. younger MUD in patients older than 50 years with AML in remission using posttransplant cyclophosphamide. Leukemia. 2024;38(9):2016-22. https://doi.org/10.1038/s41375-024-02359-8 DOI: https://doi.org/10.1038/s41375-024-02359-8
7. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-83. https://doi.org/10.1182/blood-2007-06-097386 DOI: https://doi.org/10.1182/blood-2007-06-097386
8. Besse K, Maiers M, Confer D, Albrecht M. On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source. Biol Blood Marrow Transplant. 2016;22(3):410-7. https://doi.org/10.1016/j.bbmt.2015.09.012 DOI: https://doi.org/10.1016/j.bbmt.2015.09.012
9. Shaw BE, Logan BR, Spellman SR, Marsh SGE, Robinson J, Pidala J, Hurley C, Barker J, Maiers M, Dehn J, Wang H, Haagenson M, Porter D, Petersdorf EW, Woolfrey A, Horowitz MM, Verneris M, Hsu KC, Fleischhauer K, Lee SJ. Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most. Biol Blood Marrow Transplant. 2018;24(5):1049-56. https://doi.org/10.1016/j.bbmt.2018.02.006 DOI: https://doi.org/10.1016/j.bbmt.2018.02.006
10. Rezvani AR, Storer BE, Guthrie KA, Schoch HG, Maloney DG, Sandmaier BM, Storb R. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(1):105-12. https://doi.org/10.1016/j.bbmt.2014.09.021 DOI: https://doi.org/10.1016/j.bbmt.2014.09.021
11. Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, Champlin RE, Confer DL, DiPersio JF, Fernandez-Viña M, Hartzman RJ, Horowitz MM, Hurley CK, Karanes C, Maiers M, Mueller CR, Perales MA, Setterholm M, Woolfrey AE, Yu N, Eapen M. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127(2):260-7. https://doi.org/10.1182/blood-2015-08-663823 DOI: https://doi.org/10.1182/blood-2015-08-663823
12. Worel N, Aljurf M, Anthias C, Buser AS, Cody M, Fechter M, Galeano S, Greinix HT, Kisch AM, Koh MBC, Mengling T, Nicoloso G, Niederwieser D, Pulsipher MA, Seber A, Shaw BE, Stefanski HE, Switzer GE, Szer J, van Walraven SM, Yang H, Halter JP. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues. Lancet Haematol. 2022;9(8):e605-14. https://doi.org/10.1016/S2352-3026(22)00184-3 DOI: https://doi.org/10.1016/S2352-3026(22)00184-3
13. Spellman SR, Sparapani R, Maiers M, Shaw BE, Laud P, Bupp C, He M, Devine SM, Logan BR. Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes. Blood Adv. 2024;8(23):6082-7. https://doi.org/10.1182/bloodadvances.2024013756 DOI: https://doi.org/10.1182/bloodadvances.2024013756
14. Abid MB, Estrada-Merly N, Zhang MJ, Chen K, Allan D, Bredeson C, Sabloff M, Guru Murthy GS, Badar T, Hashmi S, Aljurf M, Litzow MR, Kebriaei P, Hourigan CS, Saber W. Impact of donor age on allogeneic hematopoietic cell transplantation outcomes in older adults with acute myeloid leukemia. Transplant Cell Ther. 2023;29(9):578.e1-e9. https://doi.org/10.1016/j.jtct.2023.06.020 DOI: https://doi.org/10.1016/j.jtct.2023.06.020
15. Abid MB, Estrada-Merly N, Zhang MJ, Chen K, Bredeson C, Allan D, Sabloff M, Marks DI, Litzow M, Hourigan C, Kebriaei P, Saber W. Younger matched unrelated donors confer decreased relapse risk compared to older sibling donors in older patients with B-cell acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2023;29(10):611-8. https://doi.org/10.1016/j.jtct.2023.07.015 DOI: https://doi.org/10.1016/j.jtct.2023.07.015
16. Murthy GSG, Kim S, Hu ZH, Estrada-Merly N, Abid MB, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Diaz Perez MA, Farhadfar N, Gale RP, Ganguly S, Gergis U, Hildebrandt GC, Grunwald MR, Hashmi S, Hossain NM, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Hamilton BK, Lazarus HM, Liesveld J, Litzow M, Marks DI, Murthy HS, Nathan S, Nazha A, Nishihori T, Patel SS, Pawarode A, Rizzieri D, Savani B, Seo S, Solh M, Ustun C, van der Poel M, Verdonck LF, Vij R, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors. JAMA Oncol. 2022;8(3):404-11. https://doi.org/10.1001/jamaoncol.2021.6846 DOI: https://doi.org/10.1001/jamaoncol.2021.6846
17. DeZern AE, Franklin C, Tsai HL, Imus PH, Cooke KR, Varadhan R, Jones RJ. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2021;5(5):1360-8. https://doi.org/10.1182/bloodadvances.2020003922 DOI: https://doi.org/10.1182/bloodadvances.2020003922
18. Marcoux C, Marin D, Ramdial J, AlAtrash G, Alousi AM, Oran B, Kebriaei P, Popat UR, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Am J Hematol. 2023;98(5):712-9. https://doi.org/10.1002/ajh.26870 DOI: https://doi.org/10.1002/ajh.26870
19. Mariotti J, Raiola AM, Evangelista A, Carella AM, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, Brunello L, Merla E, Savino L, Loteta B, Console G, Fanin R, Sperotto A, Marano L, Marotta S, Frieri C, Sica S, Chiusolo P, Harbi S, Furst S, Santoro A, Bacigalupo A, Blaise D, Angelucci E, Mavilio D, Castagna L, Bruno B. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with post-transplant cyclophosphamide. Blood Adv. 2020;4(16):3900-12. https://doi.org/10.1182/bloodadvances.2020001620 DOI: https://doi.org/10.1182/bloodadvances.2020001620
20. Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, Styczynski J, Ward KN, Cesaro S; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2014;59(4):473-81. https://doi.org/10.1093/cid/ciu364 DOI: https://doi.org/10.1093/cid/ciu364
21. Kawamura S, Nakagawa D, Nagayama T, Katayama Y, Doki N, Takeda W, Nishida T, Matsuoka K, Ikeda T, Ohigashi H, Sawa M, Fukushima K, Kanda J, Serizawa K, Onizuka M, Fukuda T, Atsuta Y, Kanda Y, Nakasone H. Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT. Blood Adv. 2025;9(9):2356-65. https://doi.org/10.1182/bloodadvances.2024014408 DOI: https://doi.org/10.1182/bloodadvances.2024014408
22. Mehta RS, Choe H, Saultz J, Gong Z, Sharma P, Al-Juhaishi T, Petitto GS, Lazaryan A, Singh A, Xue E, Dimitrova D, Hyder M, McCurdy S, Im A, Huber B, Aljawai YM, Kanakry J, Milano F, Kanakry CG. Impact of donor age and donor cytomegalovirus serostatus on outcomes after related donor allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2025;100(6):987-97. https://doi.org/10.1002/ajh.27662 DOI: https://doi.org/10.1002/ajh.27662
23. Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea S, Dandoy CE, Díaz MA, Fuchs EJ, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri KV, Krem MM, Lazarus HM, Liu H, Ljungman P, Masiarz R, Mulroney C, Nathan S, Nishihori T, Page KM, Perales MA, Taplitz R, Romee R, Riches M; CIBMTR Infection and Immune Reconstitution Working Committee. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021;137(23):3291-305. https://doi.org/10.1182/blood.2020009362 DOI: https://doi.org/10.1182/blood.2020009362
24. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C. Letermovir prophylaxis for cytomegalovirus in hematopoieticcell transplantation. N Engl J Med. 2017;377(25):2433-44. https://doi.org/10.1056/NEJMoa1706640 DOI: https://doi.org/10.1056/NEJMoa1706640
25. Girmenia C, Chiusolo P, Marsili G, Piciocchi A, Micò MC, Greco R, Porto G, Galaverna F, Bonifazi F, Cutini I, Malagola M, Bramanti S, Busca A, Carella AM, Carotti A, Iori AP, Onida F, Bono R, Terruzzi E, Vacca A, Rinaldi A, Cavattoni IM, Picardi A, Faraci M, Lazzarotto T, Baldanti F, Clerici P, Castagna L, Martino M, Ciceri F; Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI). The changing impact of human cytomegalovirus serology and infection on patient outcome after allogeneic hematopoietic stem cell transplantation: an Italian prospective multicenter survey in the era of letermovir prophylaxis. Open Forum Infect Dis. 2025;12(5):ofaf233. https://doi.org/10.1093/ofid/ofaf233 DOI: https://doi.org/10.1093/ofid/ofaf233
26. Murthy GSG, Logan BR, Bo-Subait S, Beitinjaneh A, Devine S, Farhadfar N, Gowda L, Hashmi S, Lazarus H, Nathan S, Sharma A, Yared JA, Stefanski HE, Pulsipher MA, Hsu JW, Switzer GE, Panch SR, Shaw BE. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. Am J Hematol. 2023;98(4):608-19. https://doi.org/10.1002/ajh.26834 DOI: https://doi.org/10.1002/ajh.26834
27. Kimura F, Sato K, Kobayashi S, Ikeda T, Sao H, Okamoto S, Miyamura K, Mori S, Akiyama H, Hirokawa M, Ohto H, Ashida H, Motoyoshi K. Impact of ABO-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. Haematologica. 2008;93(11):1686-93. https://doi.org/10.3324/haematol.12933 DOI: https://doi.org/10.3324/haematol.12933
28. Balduzzi A, Bönig H, Jarisch A, Nava T, Ansari M, Cattoni A, Prunotto G, Lucchini G, Krivan G, Matic T, Kalwak K, Yesilipek A, Ifversen M, Svec P, Buechner J, Vettenranta K, Meisel R, Lawitschka A, Peters C, Gibson B, Dalissier A, Corbacioglu S, Willasch A, Dalle JH, Bader P; EBMT Pediatric Diseases Working Party. ABO incompatible graft management in pediatric transplantation. Bone Marrow Transplant. 2021;56(1):84-90. https://doi.org/10.1038/s41409-020-0981-7 DOI: https://doi.org/10.1038/s41409-020-0981-7
29. Worel N. ABO-mismatched allogeneic hematopoietic stem cell transplantation. Transfus Med Hemother. 2016;43(1):3-12. https://doi.org/10.1159/000441507 DOI: https://doi.org/10.1159/000441507
30. Brierley CK, Littlewood TJ, Peniket AJ, Gregg R, Ward J, Clark A, Parker A, Malladi R, Medd P. Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic stem cell transplantation. Bone Marrow Transplant. 2015;50(7):931-8. https://doi.org/10.1038/bmt.2015.51 DOI: https://doi.org/10.1038/bmt.2015.51
31. Loren AW, Bunin GR, Boudreau C, Champlin RE, Cnaan A, Horowitz MM, Loberiza FR, Porter DL. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(7):758-69. https://doi.org/10.1016/j.bbmt.2006.03.015 DOI: https://doi.org/10.1016/j.bbmt.2006.03.015
32. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched related hematopoietic stem cell transplants. Blood. 2004;103(1):347-52. https://doi.org/10.1182/blood-2003-07-2603 DOI: https://doi.org/10.1182/blood-2003-07-2603
33. Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO. Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? Biol Blood Marrow Transplant. 2015;21(4):713-9. https://doi.org/10.1016/j.bbmt.2014.12.018 DOI: https://doi.org/10.1016/j.bbmt.2014.12.018
34. Azari M, Barkhordar M, Bahri T, Rad S, Fumani HK, Mousavi SA, Shiraji ST, Azari M, Shafaroudi P, Vaezi M. Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study. Front Oncol. 2024;14:1339605. https://doi.org/10.3389/fonc.2024.1339605 DOI: https://doi.org/10.3389/fonc.2024.1397607
35. Takano K, Tamaki M, Inoue Y, Kawamura S, Terakura S, Keino D, Kako S, Fujiwara SI, Doki N, Nishida T, Hasegawa Y, Asada N, Sawa M, Tanaka M, Uchida N, Hiramoto N, Nakamae H, Kawamura K, Fukuda T, Ohbiki M, Atsuta Y, Kanda Y, Yakushijin K, Nakasone H. The impact of female-to-male allogeneic hematopoietic cell transplantation on survival outcomes varies by recipient age. Transplant Cell Ther. 2026:S2666-6367(26)00429-X. https://doi.org/10.1016/j.jtct.2026.05.036 DOI: https://doi.org/10.1016/j.jtct.2026.05.036
36. Kato M, Yamashita T, Suzuki R, Matsumoto K, Nishimori H, Takahashi S, Iwato K, Nakaseko C, Kondo T, Imada K, Kimura F, Ichinohe T, Hashii Y, Kato K, Atsuta Y, Taniguchi S, Fukuda T. Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation. Leukemia. 2016;30(8):1742-5. https://doi.org/10.1038/leu.2016.23 DOI: https://doi.org/10.1038/leu.2016.23
37. Williams LS, Williams KM, Gillis N, Bolton K, Damm F, Deuitch NT, Farhadfar N, Gergis U, Keel SB, Michelis FV, Panch SR, Porter CC, Sucheston-Campbell L, Tamari R, Stefanski HE, Godley LA, Lai C. Donor-derived malignancy and transplantation morbidity: risks of patient and donor genetics in allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2024;30(3):255-67. https://doi.org/10.1016/j.jtct.2023.10.018 DOI: https://doi.org/10.1016/j.jtct.2023.10.018
38. Godley LA, DiNardo CD, Bolton K. Germline predisposition in hematologic malignancies: testing, management, and implications. Am Soc Clin Oncol Educ Book. 2024;44:e432218. https://doi.org/10.1200/EDBK_432218 DOI: https://doi.org/10.1200/EDBK_432218
39. Jimenez AMJ, Spellman SR, Politikos I, McCurdy SR, Devine SM, Al Malki MM, Bolon YT, Lee SJ, Dehn J, Pidala J, Maiers M, Askar M, Malmberg C, Auletta JJ, Stefanski H, Broglie L, Qayed M, Horwitz M, Wilder JS, Gooptu M, Shaffer BC. Allogeneic hematopoietic cell donor selection: contemporary guidelines from the NMDP/CIBMTR. Transplant Cell Ther. 2025;31(12):973-88. https://doi.org/10.1016/j.jtct.2025.07.004 DOI: https://doi.org/10.1016/j.jtct.2025.07.004
40. Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, Artz A, van Besien K, Larson RA, Lee MK, Segal JP, King MC, Walsh T, Shimamura A, Keel SB, Churpek JE, Godley LA. Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donor-derived malignancy. Biol Blood Marrow Transplant. 2016;22(11):2100-3. https://doi.org/10.1016/j.bbmt.2016.08.002 DOI: https://doi.org/10.1016/j.bbmt.2016.08.002
41. Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Corbacioglu S, Kenyon M, Aljurf M, Bonfim C, Makishima H, Niemeyer C, Fenaux P, Zebisch A, Hamad N, Chalandon Y, Hellström-Lindberg E, Voso MT, Mecucci C, Duarte FB, Sebert M, Fontbrune FS, Soulier J, Shimamura A, Lindsley RC, Maciejewski JP, Calado RT, Yakoub-Agha I, McLornan DP. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023;10(12):e994-e1005. https://doi.org/10.1016/S2352-3026(23)00265-X DOI: https://doi.org/10.1016/S2352-3026(23)00265-X
42. Martin AR, Bilbao-Sieyro C, Stuckey R, Dominguez LMG, Alvarez MMP, Ortega YF, Fleitas CA, Rodriguez-Medina C, Pinedo LG, Ochando MT, Cruz JG, Curbelo AM, García LR, Cruz CJA, Casares MTG. The germline challenge in allogeneic transplantation: from donor selection to outcomes. Bone Marrow Transplant. 2026;61(4):500-2. https://doi.org/10.1038/s41409-026-02806-3 DOI: https://doi.org/10.1038/s41409-026-02806-3
43. Tesi B, Robelius A, Baskin B, Lazarevic V, Deneberg S, Hoglund M, Fogelstrand L, Ungerstedt J, Pandzic T, Tobiasson M, Garelius HG, Kuchinskaya E, Persson F, Agerstam H, Hallbook H, Fioretos T, Nordin J, Norberg A, Thuresson AC, Lehmann S, Ladenvall C, Barbany G, Vennstrom L, Ejerblad E, Cavelier L, Cammenga J, Jadersten M, Hellstrom-Lindberg E, Baliakas P. Validation of guidelines for genetic investigation of myeloid neoplasms with germline predisposition: results from a prospective cohort study. Clin Cancer Res. 2025;31(14):3062-71. https://doi.org/10.1158/1078-0432.CCR-24-4251 DOI: https://doi.org/10.1158/1078-0432.CCR-24-4251
44. Ahn JS, Park JH, Lee C, Song IC, Kim MY, Sohn SK, Yhim HY, Park Y, Kim I, Shin HJ, Park SK, Kim SH, Cheong JW, Lee HS, Lee H, Bae SH, Choi Y, Lee HG, Do YR, Han JJ, Kim MK, Park S, Kim HJ, Kim HJ. Serial next generation sequencing for detecting germline predisposition in acute myeloid leukemia. Haematologica. 2026;111(2):718-23. https://doi.org/10.3324/haematol.2025.287794 DOI: https://doi.org/10.3324/haematol.2025.287794
45. World Marrow Donor Association (WMDA). International Standards for Unrelated Haematopoietic Stem Cell Donor Registries [Internet]. WMDA; 2024 [cited 2026 May 30]. Available at: https://wmda.info/storage/2024/01/2024-WMDA-Stnds_20240101-final.pdf
46. Halter J, Kodera Y, Urbano-Ispizua A, Greinix HT, Schmitz N, Favre G, Baldomero H, Niederwieser D, Apperley JF, Gratwohl A. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 2009;94(1):94-101. https://doi.org/10.3324/haematol.13668 DOI: https://doi.org/10.3324/haematol.13668
47. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer. 2006;46(4):422-33. https://doi.org/10.1002/pbc.20708 DOI: https://doi.org/10.1002/pbc.20708
48. Bitan M, van Walraven SM, Worel N, Ball LM, Styczynski J, Torrabadella M, Witt V, Shaw BE, Seber A, Yabe H, Greinix HT, Peters C, Gluckman E, Rocha V, Halter J, Pulsipher MA. Determination of eligibility in related pediatric hematopoietic cell donors: ethical and clinical considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. Biol Blood Marrow Transplant. 2016;22(1):96-103. https://doi.org/10.1016/j.bbmt.2015.08.017 DOI: https://doi.org/10.1016/j.bbmt.2015.08.017
49. Katz AL, Macauley RC, Mercurio MR, Moon MR, Okun AL, Opel DJ, Statter MB; Committee on Bioethics. Informed consent in decision-making in pediatric practice. Pediatrics. 2016;138(2):e20161484. https://doi.org/10.1542/peds.2016-1484 DOI: https://doi.org/10.1542/peds.2016-1485
50. Delbon P, Attico F, Nadai M, Almici C, Ferrari E, Malagola M, Conti A. Ethical and legal issues in haematopoietic stem cells (HSC) donation: the controversial and problematic aspects in minors. Acta Biomed. 2024;95(3):e2024082. https://doi.org/10.23750/abm.v95i3.15820
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Simone Cunha Maradei, Mariana Torres Mazzi, Clara Werner Rosemberg, Luiz Fernando Bouzas
This work is licensed under a Creative Commons Attribution 4.0 International License.
